Tags

Type your tag names separated by a space and hit enter

The efficacy of aliskiren, a direct renin inhibitor, in the treatment of hypertension.
Rev Cardiovasc Med. 2007; 8 Suppl 2:S22-30.RC

Abstract

Aliskiren is a potent, highly specific renin inhibitor with better oral bioavailability than earlier renin inhibitors and a long plasma half-life that makes it suitable for once-daily dosing. The efficacy and safety of aliskiren in treating hypertension has been studied in clinical trials both as monotherapy, comparing it with existing antihypertensive therapies, and in combination with other antihypertensive agents, including the diuretic hydrochlorothiazide, the angiotensin-converting enzyme inhibitor ramipril, and the calcium channel blocker amlodipine. From the extensive database acquired to date, it is clear that aliskiren is an effective antihypertensive agent, with once-daily administration resulting in dose-dependent systolic and diastolic blood pressure reductions. Combinations with existing antihypertensives are producing promising additional blood pressure-lowering effects.

Authors+Show Affiliations

Division of Cardiovascular Diseases, Western Pennsylvania Hospital and Temple University School of Medicine (Clinical Campus), Pittsburgh, Pennsylvania, USA.No affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

17401313

Citation

Gradman, Alan H., and Darren Traub. "The Efficacy of Aliskiren, a Direct Renin Inhibitor, in the Treatment of Hypertension." Reviews in Cardiovascular Medicine, vol. 8 Suppl 2, 2007, pp. S22-30.
Gradman AH, Traub D. The efficacy of aliskiren, a direct renin inhibitor, in the treatment of hypertension. Rev Cardiovasc Med. 2007;8 Suppl 2:S22-30.
Gradman, A. H., & Traub, D. (2007). The efficacy of aliskiren, a direct renin inhibitor, in the treatment of hypertension. Reviews in Cardiovascular Medicine, 8 Suppl 2, S22-30.
Gradman AH, Traub D. The Efficacy of Aliskiren, a Direct Renin Inhibitor, in the Treatment of Hypertension. Rev Cardiovasc Med. 2007;8 Suppl 2:S22-30. PubMed PMID: 17401313.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The efficacy of aliskiren, a direct renin inhibitor, in the treatment of hypertension. AU - Gradman,Alan H, AU - Traub,Darren, PY - 2007/4/3/pubmed PY - 2007/10/5/medline PY - 2007/4/3/entrez SP - S22 EP - 30 JF - Reviews in cardiovascular medicine JO - Rev Cardiovasc Med VL - 8 Suppl 2 N2 - Aliskiren is a potent, highly specific renin inhibitor with better oral bioavailability than earlier renin inhibitors and a long plasma half-life that makes it suitable for once-daily dosing. The efficacy and safety of aliskiren in treating hypertension has been studied in clinical trials both as monotherapy, comparing it with existing antihypertensive therapies, and in combination with other antihypertensive agents, including the diuretic hydrochlorothiazide, the angiotensin-converting enzyme inhibitor ramipril, and the calcium channel blocker amlodipine. From the extensive database acquired to date, it is clear that aliskiren is an effective antihypertensive agent, with once-daily administration resulting in dose-dependent systolic and diastolic blood pressure reductions. Combinations with existing antihypertensives are producing promising additional blood pressure-lowering effects. SN - 1530-6550 UR - https://www.unboundmedicine.com/medline/citation/17401313/The_efficacy_of_aliskiren_a_direct_renin_inhibitor_in_the_treatment_of_hypertension_ L2 - https://medlineplus.gov/highbloodpressure.html DB - PRIME DP - Unbound Medicine ER -